(Q40397239)

20 September 2017

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs (English)

1 reference

20 September 2017

13

David Montefiori

1 reference

20 September 2017

15

Bernard Moss

1 reference

20 September 2017

2

Linda Wyatt

1 reference

20 September 2017

16

Harriet Robinson

1 reference

20 September 2017

17

Janet McNicholl

1 reference

20 September 2017

10

Jennifer Vogt

1 reference

20 September 2017

1

Dennis Ellenberger

1 reference

20 September 2017

4

Suzan Buge

1 reference

20 September 2017

7

Carlos A Sariol

1 reference

20 September 2017

8

Melween Martinez

1 reference

20 September 2017

9

Michael Monsour

1 reference

20 September 2017

14

Edmundo Kraiselburd

1 reference

20 September 2017

Bin Li

3

1 reference

20 September 2017

Nattawan Lanier

5

1 reference

20 September 2017

I Vanesssa Rodriguez

6

1 reference

20 September 2017

James Smith

11

1 reference

20 September 2017

Ronald Otten

12

1 reference

20 September 2017

Salvatore Butera

18

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

20 September 2017

1 reference

20 September 2017

340

1 reference

20 September 2017

1

1 reference

20 September 2017

21-32

1 reference

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Development of a DNA-MVA/HIVA vaccine for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Active human immunodeficiency virus protease is required for viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

IL-12/GM-CSF Coadministration in an SIV DNA Prime/Protein Boost Protocol Enhances Gag-Specific T Cells But Not Virus-Specific Neutralizing Antibodies in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Direct gene transfer into mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

Simian immunodeficiency virus DNA vaccine trial in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.06.014

1 reference

20 September 2017

1 reference